Ticker Details
Inovio Pharmaceuticals, Inc. Inovio Pharmaceuticals Inc is a clinical stage biopharmaceutical company. It develops active DNA immunotherapies and vaccines in combination with proprietary electroporation delivery devices to prevent and treat cancers and infectious diseases.
IPO Date:	August 23, 1999
Sector:	Healthcare
Industry:	Biotech
Market Cap:	$122.01M
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$0.18 | 4.19%
Avg Daily Range (30 D):	$0.05 | 5.10%
Avg Daily Range (90 D):	$0.05 | 4.08%

Institutional Daily Volume
Avg Daily Volume:	2.94M
Avg Daily Volume (30 D):	4.22M
Avg Daily Volume (90 D):	3.04M

Trade Size
Avg Trade Size (Sh.):	276
Avg Trade Size (Sh.) (30 D):	380
Avg Trade Size (Sh.) (90 D):	365

Institutional Trades
Total Institutional Trades:	3,233
Avg Institutional Trade:	$1.7M
Avg Institutional Trade (30 D):	$2.97M
Avg Institutional Trade (90 D):	$1.76M
Avg Institutional Trade Volume:	.02M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$2.58M
Avg Closing Trade (30 D):	$1.67M
Avg Closing Trade (90 D):	$1.67M
Avg Closing Volume:	49.21K

News

Jul 21, 2026 @ 5:00 PM Correction: Head and Neck Squamous Cell Carcinoma ... Source: Na

Jul 13, 2026 @ 5:00 PM Head and Neck Squamous Cell Carcinoma Market is Pr... Source: Na

Jun 16, 2026 @ 5:00 PM Glioblastoma Clinical Trial Landscape Expands: Ove... Source: Delveinsight

Apr 7, 2026 @ 7:46 PM Pomerantz Law Firm Announces the Filing of a Class... Source: Pomerantz Llp

Apr 7, 2026 @ 4:00 PM DEADLINE ALERT for PSFE, INO, KD: Law Offices of H... Source: Law Offices Of Howard G. Smith

Financials
	TTM	Q2 2026	Q1 2026
Basic EPS	$-.91	$-.07	$-.28
Diluted EPS	$-.91	$-.07	$-.28
Revenue	$M	$M	$M
Gross Profit
Net Income / Loss	$-67.43M	$-6.01M	$-19.68M
Operating Income / Loss	$-79.26M	$-18.62M	$-21.95M
Cost of Revenue
Net Cash Flow	$7.17M	$5.25M	$-18M
PE Ratio

Splits
Jan 25, 2024	1:12
Jun 09, 2014	1:4
Jun 06, 2014	1:4
Sep 13, 2004	1:4